ProPhase Labs, Inc. 8-K

What Happened
ProPhase Labs, Inc. (PRPH) announced in an 8-K that on December 29, 2025 it received a letter from Nasdaq stating the company did not regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 bid price. Nasdaq informed the company that trading of its common stock will be suspended at the opening of business on January 5, 2026, and that Nasdaq will file a Form 25 with the SEC to remove the securities from listing and registration. ProPhase says it intends to timely request a hearing before the Nasdaq Hearings Panel to appeal the determination and is applying for quotation of its common stock on the OTC Markets.

Key Details

• Nasdaq Rule referenced: Listing Rule 5550(a)(2) — $1.00 minimum bid requirement.
• Compliance timeline: initial 180-day period plus an additional 180-day period expired on December 22, 2025.
• Nasdaq action: trading suspension effective at market open January 5, 2026; Nasdaq will file Form 25 to delist.
• Company response: will request a hearing before the Nasdaq Hearings Panel and is applying to have its shares quoted on the OTC Markets.

Why It Matters
A suspension and delisting from Nasdaq is a material change for shareholders. If Nasdaq proceeds with removal, the stock will move off a national exchange and may trade on the OTC Markets, which can mean lower liquidity, wider bid-ask spreads, and reduced visibility among institutional investors. The company’s appeal and any outcome of the Nasdaq hearing determine whether it can remain listed; meanwhile investors should monitor ProPhase’s filings and trading venue updates closely.